RICHMOND, Va.--(BUSINESS WIRE)--ImmunArray, a privately held molecular device company dedicated to the development of novel, blood-based in vitro diagnostic tests, has completed a prospective clinical study involving more than 500 patients with mild traumatic brain injury. The study adds to the company’s growing development capability, now numbering more than 11,000 curated blood samples that contain a range of clinical data, including biomarkers, imaging and psychiatric test results. Begun in early 2014, the study followed patients across multiple time points for up to six months.
“There are currently no simple tools for aiding emergency physicians or allied health professionals on the playing field in treating those who have sustained a mild traumatic brain injury. There also is no method to educate patients about the diagnosis or prognosis of their injury,” said Donna Edmonds, CEO of ImmunArray. “The data from this large cohort of patient testing greatly enhances our ability to continue development programs with key platform partners for a simple blood test at the point of care and our own 'return-to-play' testing from our CLIA lab in Richmond.”
ImmunArray will present data from this study later this month at Neurotrauma 2017, the annual conference of the National Neurotrauma Society. The company has presented at eight conferences on brain injury in the last two years.
ImmunArray was a grant recipient of the GE-NFL Head Health Challenge and has secured additional corporate funding to conduct research into the use of biomarkers to identify traumatic brain injury. It has a broad intellectual property portfolio of licensed and company-filed patents in brain injury, many of which were licensed from Johns Hopkins University.
Founded in 2006 and co-located in Rehovot, Israel and Richmond, Va., ImmunArray’s novel blood-based testing platform supports the diagnosis and management of complex acute and chronic immune and neurodegenerative diseases. The company designs and analyzes sets of biomarkers known to be linked to a particular condition and develops tests on platforms that are most appropriate to facilitate the adoption of additional tests. The company’s first commercial test, the SLE-Key® Rule-Out Test, is used to assist physicians in ruling out Systemic Lupus Erythematosus (SLE) or lupus as part of a differential diagnosis. The company has a pipeline of products in development to support diagnosis and management of other auto-immune and neurological diseases.